0.2116

8.79% -0.0204

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $0.2116, with a volume of 1.24M. It is down -8.79% in the last 24 hours and down -30.46% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$0.232

Open:

$0.2257

24h Volume:

1.24M

Relative Volume:

0.37

Market Cap:

$36.75M

Revenue:

Net Income/Loss:

$-16.76M

P/E Ratio:

-2.645

EPS:

-0.08

Net Cash Flow:

$-132.97M

1W Performance:

+0.76%

1M Performance:

-30.46%

6M Performance:

-59.61%

1Y Performance:

-82.66%

1-Day Range:

$0.202

$0.2299

1-Week Range:

$0.1876

$0.232

52-Week Range:

$0.1876

$1.39

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1159)

Industry

Biotechnology (667)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

143

Twitter

@x4pharma

Next Earnings Date

2025-03-25

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	0.2116	36.75M	0	-16.76M	-132.97M	-0.08
VRTX Vertex Pharmaceuticals Inc	475.49	122.24B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	546.39	59.73B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	546.22	33.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	226.28	29.29B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	208.31	22.44B	3.81B	-644.79M	-669.77M	-6.24

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

Apr 10, 2025

X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton - MarketScreener

Apr 10, 2025

Apr 09, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - BioSpace

Apr 09, 2025

Apr 08, 2025

Fierce Biotech Layoff Tracker 2025: Lyell lets go of 73 workers; Relay sheds staff again - Fierce Biotech

Apr 08, 2025

Apr 04, 2025

Now Pharma Inc looks for cure as Trump delivers dose of anxiety - The Economic Times

Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 04, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Apr 04, 2025

Apr 03, 2025

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow

Apr 03, 2025

Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - BioSpace

Apr 01, 2025

Mar 31, 2025

Ionis to present at upcoming investor conferences - Quantisnow

Mar 31, 2025

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 31, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN

Mar 31, 2025

Mar 29, 2025

Research Analysts Issue Forecasts for XFOR FY2028 Earnings - Defense World

Mar 29, 2025

Mar 28, 2025

X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025

Mar 27, 2025